Gengos Andrew 4
4 · Terns Pharmaceuticals, Inc. · Filed Jun 16, 2025
Insider Transaction Report
Form 4
Gengos Andrew
Chief Financial Officer
Transactions
- Purchase
Common Stock
2025-06-13$3.75/sh+5,000$18,750→ 5,000 total - Purchase
Common Stock
2025-06-16$3.95/sh+5,000$19,733→ 15,000 total - Purchase
Common Stock
2025-06-13$3.72/sh+5,000$18,600→ 10,000 total